COPENHAGEN, September 27 /PRNewswire/ --

- Summary:  Genmab has Amended the Design of the Ofatumumab Pivotal 
Study in Rituximab Refractory Follicular Non-Hodgkin's lymphoma and Reduced 
the Number of Patients to Approximately 81.

COPENHAGEN, September 27 /PRNewswire/ --

Genmab A/S (OMX: GEN) announced today it has amended the design of an
ongoing pivotal study of ofatumumab (HuMax-CD20(R)) in rituximab refractory
follicular non-Hodgkin's lymphoma (NHL) to a single arm trial that will now
include approximately 81 patients. All patients will receive one infusion of
300 mg of ofatumumab followed by 7 weekly infusions of 1000 mg of ofatumumab.
The original study design included 162 patients, who would have received one
infusion of 300 mg of ofatumumab followed by 7 weekly infusions of either 500
or 1000 mg of ofatumumab. This is the first study of ofatumumab dedicated to
patients with rituximab-refractory follicular lymphoma.

In order to establish that ofatumumab is efficacious in this refractory
setting, reducing the number of patients in the trial will help to expedite a
result. The lower dose (500 mg) was dropped to reduce the total number of
patients to be accrued and ensure that these very sick patients receive the
maximum dose. Data from patients who were already treated in the 500 mg dose
group will be analyzed for safety and included in the secondary efficacy
analysis, but will not be included in the primary efficacy analysis.

"This change to the pivotal study design will allow us to treat all the
refractory patients with a higher dose level of ofatumumab, allowing the
maximum opportunity for response and longer lasting effects in this patient
population," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
Ofatumumab is an investigational drug being developed under a co-development
and commercialization agreement between Genmab and GlaxoSmithKline. It is not
yet approved in any market.

About Genmab A/S

Genmab is a leading international biotechnology company focused on
developing fully human antibody therapeutics for unmet medical needs. Using
unique, cutting-edge antibody technology, Genmab's world class discovery and
development teams have created and developed an extensive pipeline of
products for potential treatment of a variety of diseases including cancer
and autoimmune disorders. As Genmab advances towards a commercial future, we
remain committed to our primary goal of improving the lives of patients who
are in urgent need of new treatment options.

For more information on Genmab's products and technology, visit
http://www.genmab.com.

This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product manufacturing, the
lack of market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab
is not under an obligation to up-date statements regarding the future
following the publication of this release; nor to confirm such statements in
relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM);
HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all
trademarks of Genmab A/S.

Stock Exchange Release no. 42/2007

Contact: 

    Helle Husted
    Sr. Director 
    Investor Relations
    T: +45-33-44-77-30 
    M: +45-25-27-47-13 
    E: th@genmab.com